Prostate Cancer - Results from #28640

Abiraterone acetate significantly improved overall survival for patients with metastatic advanced prostate cancer October 11, 2010

Study of investigational agent abiraterone acetate for metastatic advanced prostate cancer unblinded after meeting pre-determined criteria September 10, 2010

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics - Abstract May 31, 2010

Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer - Abstract May 27, 2010

Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer - Abstract May 27, 2010

5A prospective survey of current prostate biopsy practices among oncological urologists - Abstract April 29, 2010

Management of Urological Cancers During Pregnancy April 7, 2010

Editorial - Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer March 30, 2010

Abiraterone acetate for castration resistant prostate cancer - Abstract March 29, 2010

GU Cancers Symposium 2010: ASCO ASTRO SUO - Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC) - March 9, 2010

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy - Abstract March 2, 2010

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with Docetaxel-treated castration-resistant prostate cancer - Abstract March 1, 2010

Significant and sustained antitumor activity in post-Docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate - Abstract March 1, 2010

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer - Abstract February 8, 2010

Does every prostate cancer need active intervention? - Multimedia Presentation October 29, 2009

A feasibility study of novel ultrasonic tissue characterization for prostate-cancer diagnosis: 2D spectrum analysis of in vivo data with histology as gold standard - Abstract October 12, 2009

ASCO 2009 - Phase II Multicenter Study of Chemotherapy-Naive Castration-Resistant Prostate Cancer (CRPC) not Exposed to Ketoconazole, Treated with Abiraterone Acetate (AA) Plus Prednisone - Session Highlights June 1, 2009

ASCO 2009 - A Multicenter Phase II Study of Abiraterone Acetate (AA) in Docetaxel Pretreated Castration-Resistant Prostate Cancer (CRPC) Patients - Session Highlights June 1, 2009

ASCO 2009 - Circulating Tumor Cells (CTC) in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) Receiving Abiraterone Acetate (AA) after Failure of Docetaxel-Based Chemotherapy - Session Highlights June 1, 2009

Working patterns and perceived contribution of prostate cancer clinical nurse specialists: A mixed method investigation - Abstract April 20, 2009

Page 1433 of 1434